2,129
Views
9
CrossRef citations to date
0
Altmetric
Editorial

Soluble CD163 is a potential biomarker in systemic sclerosis

ORCID Icon &
Pages 197-199 | Received 05 Dec 2018, Accepted 16 Jan 2019, Published online: 22 Jan 2019

References

  • Varga J, Trojanowska M, Kuwana M. Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities. J scleroderma relat disord. 2017;2(3):137–152.
  • LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15(2):202–205.
  • Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol. 2011;11(11):723–737.
  • Matsushita T, Takehara K. An update on biomarker discovery and use in systemic sclerosis. Expert Rev Mol Diagn. 2017;17(9):823–833.
  • Kristiansen M, Graversen JH, Jacobsen C, et al. Identification of the haemoglobin scavenger receptor. Nature. 2001;409(6817):198–201.
  • Frings W, Dreier J, Sorg C. Only the soluble form of the scavenger receptor CD163 acts inhibitory on phorbol ester-activated T-lymphocytes, whereas membrane-bound protein has no effect. FEBS Lett. 2002;526(1–3):93–96.
  • Higashi-Kuwata N, Jinnin M, Makino T, et al. Characterization of monocyte/macrophage subsets in the skin and peripheral blood derived from patients with systemic sclerosis. Arthritis Res Ther. 2010;12(4):R128.
  • Mathai SK, Gulati M, Peng X, et al. Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype. Lab Invest. 2010;90(6):812–823.
  • Christmann RB, Sampaio-Barros P, Stifano G, et al. Association of interferon- and transforming growth factor beta-regulated genes and macrophage activation with systemic sclerosis-related progressive lung fibrosis. Arthritis Rheumatol. 2014;66(3):714–725.
  • Nakayama W, Jinnin M, Makino K, et al. Serum levels of soluble CD163 in patients with systemic sclerosis. Rheumatol Int. 2012;32(2):403–407.
  • Hassan WA, Baraka EA, Elnady BM, et al. Serum soluble CD163 and its association with various disease parameters in patients with systemic sclerosis. Eur J Rheumatol. 2016;3(3):95–100.
  • Shimizu K, Ogawa F, Yoshizaki A, et al. Increased serum levels of soluble CD163 in patients with scleroderma. Clin Rheumatol. 2012;31(7):1059–1064.
  • Bielecki M, Kowal K, Lapinska A, et al. Increased release of soluble CD163 by the peripheral blood mononuclear cells is associated with worse prognosis in patients with systemic sclerosis. Adv Med Sci. 2013;58(1):126–133.
  • Kowal-Bielecka O, Bielecki M, Guiducci S, et al. High serum sCD163/sTWEAK ratio is associated with lower risk of digital ulcers but more severe skin disease in patients with systemic sclerosis. Arthritis Res Ther. 2013;15(3):R69.
  • Frantz C, Pezet S, Avouac J, et al. Soluble CD163 as a potential biomarker in systemic sclerosis. Dis Markers. 2018;2018:8509583.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.